Previous 10 | Next 10 |
Moleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) PR Newswire Preliminary results demonstrate a durable complete response at starting dose level in eld...
Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer Models PR Newswire Sponsored research data presented in a poster presentation at the American Association f...
2023-03-23 14:02:02 ET Moleculin Biotech, Inc. (MBRX) Q4 2022 Earnings Conference Call March 23, 2023 08:30 ET Company Participants Jenene Thomas - Investor Relations Walter Klemp - Chairman and Chief Executive Officer John Paul Waymack - Senior Chief Medical Off...
2023-03-23 13:21:04 ET Moleculin Biotech ( NASDAQ: MBRX ) was trading around -9% on Thursday after its net loss widened from $6.7M in 2021 to $29M in 2022. The drug developer's pipeline is yet to generate revenue, but Moleculin Biotech "positive and highly encour...
2023-03-23 07:52:36 ET Moleculin Biotech press release ( NASDAQ: MBRX ): FY net loss of $29M As of December 31, 2022, we had cash and cash equivalents of $43.1 million and prepaid expenses and other current assets of $2.5 million. The Company believes that this cash i...
Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update PR Newswire – 2022 marked by continued execution and growing body of positive data across clinical and preclinical development programs – Sufficient capital to fund operations...
Moleculin Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials PR Newswire – Actively recruiting in three Phase 1b /2 clinical trials (with one now in Phase 2) and have re...
2023-03-21 17:35:58 ET Major earnings expected after the bell on Wednesday include: Chewy ( CHWY ) KB Home ( KBH ) Aeva Technologies ( AEVA ) Moleculin Biotech ( MBRX ) For further details see: Notable earnings after Wednesday's close
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 PR Newswire HOUSTON , March 21, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"),...
Moleculin to Present at the Oppenheimer 33rd Annual Healthcare Conference PR Newswire Presentation with live video webcast on Tuesday, March 14 th at 12:40 PM ET HOUSTON , March 13, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasda...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...
Moleculin to Present at the Virtual Investor Pitch Conference PR Newswire Live video webcast on Tuesday, June 18 th at 3:00 PM ET HOUSTON , June 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company...